Treatment results of radiation therapy for muscle-invasive bladder cancer

Strahlentherapie und Onkologie

Volumn 186, Issue 4, 2010, Pages 203-209

  Langsenlehner, T ^a   Döller, Carmen ^a   Quehenberger, Franz ^a   Stranzl Lawatsch, Heidi ^a   Langsenlehner, Uwe ^b   Pummer, Karl ^a   Kapp, Karin S ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Internal Outpatient Department   (Austria)

Author keywords

Bladder cancer; External beam radiotherapy; Local control; Organ preservation

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER DISEASE; CANCER CONTROL; CANCER INVASION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYDRONEPHROSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; RADIATION DOSE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINARY TRACT DISEASE; ADJUVANT THERAPY; BLADDER TUMOR; COMPUTER ASSISTED RADIOTHERAPY; CYSTOSCOPY; DISEASE FREE SURVIVAL; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE FRACTIONATION; RADIOTHERAPY;

AGED; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTOSCOPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; URINARY BLADDER NEOPLASMS;

EID: 77951632496     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2053-1     Document Type: Article

References (54)

1. Alvarez Moret J, Kölbl O, Bogner L. Quasi-IMAT study with conventional equipment to show high plan quality with a single gantry arc. Strahlenther Onkol 2009;185:41-48
2. Bartsch GC, Kuefer R, Gschwend JE, et al. Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol 2007;51:690-697 (Pubitemid 46097264)
3. Basillote JB, Abdelshehid C, Ahlering TE, et al. Laparoscopic assisted radical cystectomy with ileal neobladder: a comparison with the open approach. J Urol 2004;172:489-493
4. Bhatta Dhar N, Kessler TM, Mills RD, et al. Nerve-sparing radical cystectomy and orthotopic bladder replacement in female patients. Eur Urol 2007;52:1006-1014
5. Blank LE, Koedooder K, van Os R, et al. Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors Less than 5 cm in diameter. Int J Radiat Oncol Biol Phys 2007;69:454-458
6. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005;62:309-317
7. Chung PW, Bristow RG, Milosevic MF, et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 2007;25:303-309 (Pubitemid 47031001)
8. Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, et al. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 2000;154:125-132 (Pubitemid 30612910)
9. Coppin CM, Gospodarowicz MK, James K, et al. Improved Local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2901-2907
10. Cowan RA, McBain CA, Ryder WD, et al. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:197-207.
11. Danesi DT, Arcangeli G, Cruciam' E, et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: Long term results. Cancer 2004;101:2540-2548 (Pubitemid 39532283)
12. Deutschmann H, Steininger P, Nairz O, et al. "Augmented reality" in conventional simulation by projection of 3-D structures into 2-D images. A comparison with virtual methods. Strahlenther Onkol 2008;184:93-99
13. Dunst J, Diestelhorst A, Kühn R, et al. Organ-sparing treatment in muscle-invasive bladder cancer. Strahlenther Onkol 2005;181:632-637
14. Efstathiou JA, Zietman AL, Kaufman DS, et al. Bladder-sparing approaches to invasive disease. World J Urol 2006;24:517-529
15. Froehner M, Brausi MA, Herr HW, et al. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol 2009;56:443-454
16. Georg D, Georg P, Hillbrand M, et al. Assessment of improved organ at risk sparing for advanced cervix carcinoma utilizing precision radiotherapy techniques. Strahlenther Onkol. 2008;184:586-591
17. Goldobenko GV, Matveev BP, Shipilov VI, et al. Radiation treatment of bladder cancer using different fractionation regimens. Med Radiol 1991;36:14-16
18. Hart S, Skinner EC, Meyerowitz BE, et al. Quality of Life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral kock pouch. J Urol 1999;162:77-81.
19. Hata M, Miyanaga N, Tokuuye K, et al. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy. Int J Radiat Oncol Biol Phys 2006;64:1371-1379
20. Hoskin PJ, Rojas AM, Saunders MI, et al. Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial. Radiother Oncol 2009;91:120-125
21. Hulshof MC, van Andel G, Bel A, et al. Intravesical markers for delineation of target volume during external focal irradiation of bladder carcinomas. Radiother Oncol 2007;84:49-51. (Pubitemid 47030691)
22. Jemal A, Siegel R, Ward E, et al. Cancer statistics. 2008. CA Cancer J Clin 2008;58:71-96.
23. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006;176:1354-1361
24. Kaufman DS, Winter KA, Shipley WU, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paditaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009;73:833-837
25. Koga F, Kihara K, Fujii Y, et al. Favourable outcomes of patients with clinical stage T3NOMO bladder cancer treated with induction Low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study. BJU Int 2009;104:189-194
26. Köhler FM, Boda-Heggemann J, Küpper B, et al. Phantom measurements to quantify the accuracy of a commercially available cone-beam CT gray-value matching algorithm using multiple fiducials. Strahlenther Onkol 2009;185:49-55.
27. Kotwal S, Choudhury A, Johnston C, et al. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 2008;70:456-463
28. Mak RH, Zietman AL, Heney NM, et al. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int 2008;102:1345-1353
29. Mangar SA, Scurr E, Huddart RA, et al. Assessing intra-fractional bladder motion using cine-MRI as initial methodology for predictive organ Localization (POLO) in radiotherapy for bladder cancer. Radiother Oncol 2007;85:207-214 (Pubitemid 350161003)
30. Moonen L, vd Voet H, de Nijs R, et al. Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on Local control. Int J Radiat Oncol Biol Phys 1998;42:525-530 (Pubitemid 28501100)
31. Müller AC, Diestelhorst A, Kuhnt T, et al. Organ-sparing treatment of advanced bladder cancer. Paditaxel as a radiosensitizer. Strahlenther Onkol 2007;183:177-183
32. Muren LP, Redpath AT, Lord H, et al. Image-guided radiotherapy of bladder cancer: bladder volume variation and its relation to margins. Radiother Oncol 2007;84:307-313 (Pubitemid 47362400)
33. Näslund I, Nilsson B, Littbrand B. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. Acta Oncol 1994;33:397-402.
34. Perdona S, Auto ri no R, Damiano R, et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 2008;112:75-83.
35. Piet AH, Hulshof MC, Pieters BR, et al. Clinical results of a concomitant boost radiotherapy technique for muscle-invasive bladder cancer. Strahlenther Onkol 2008;184:313-318
36. Pos FJ, Hart G, Schneider C, et al. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 2006;64:1168-1173
37. Pos FJ, Hulshof M, Lebesque J, et al. Adaptive radiotherapy for invasive bladder cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2006;64:862-868 (Pubitemid 43183586)
38. Rodel C. Current status of radiation therapy and combined-modality treatment for bladder cancer. Strahlenther Onkol 2004;180:701-709 (Pubitemid 40022277)
39. Rodel C, Grabenbauer GG, Rodel F, et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000;46:1213-1221
40. Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006;24:5536-5544
41. Sabaa MA, EL-Gamal OM, Abo-Elenen M, et al. Combined modality treatment with bladder preservation for muscle invasive bladder cancer. Urol Oncol 2010;28:14-20.
42. Sauer R, Dunst J, Altendorf-Hofmann A, et al. Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys 1990;19:687-691
43. Scrimger RA, Murtha AD, Parliament MB, et al. Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors. Int J Radiat Oncol Biol Phys 2001;51:23-30.
44. Shelley MD, Barber J, Wilt T, et al. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002;3:CD002079.
45. Shimizu S, Shirato H, Kitamura K, et al. Use of an implanted marker and real-time tracking of the marker for the positioning of prostate and bladder cancers. Int J Radiat Oncol Biol Phys 2000;48:1591-1597
46. Sogni F, Brausi M, Frea B, et al. Morbidity and quality of Life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology 2008;71:919-923
47. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: Long-term results of a standard procedure. World J Urol 2006;24:296-304.
48. Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 1997;37:259-267
49. Thalmann GN, Stein JP. Outcomes of radical cystectomy. BJU Int 2008;102:1279-1288
50. van Onna IE, Oddens JR, Kok ET, et al. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. Eur Urol 2009;56:113-121
51. Weiss C, Engehausen DG, Krause FS, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007;68:1072-1080
52. Weiss C, Rodel F, Ott O, et al. Pretreatment proliferation and Local control in bladder cancer after radiotherapy with or without concurrent chemotherapy. Strahlenther Onkol 2007;183:552-556
53. Weiss C, von Römer F, Capalbo G, et al. Survivin expression as a predictive marker for Local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 2009;74:1455-1460
54. Wiezorek T, Schwahofer A, Schubert K. The influence of different IMRT techniques on the peripheral dose. A comparison between sMLM-IMRT and helical tomotherapy. Strahlenther Onkol 2009;185:696-702.